文献类型：期刊文献

中文题名：转移性结直肠癌靶向治疗和免疫治疗的研究进展

英文题名：Research progress in targeted therapy and immunotherapy of metastatic colorectal cancer

作者：魏才杰[1];屠文英[1];李云霞[1];坚胜强[1];李雯[1];李海龙(综述)[2];任拾璞(审校)[1]

第一作者：魏才杰

机构：[1]兰州石化总医院(甘肃中医药大学第四附属医院),兰州市730060;[2]甘肃中医药大学附属医院

第一机构：甘肃中医药大学第二附属医院

年份：2025

卷号：52

期号：8

起止页码：420

中文期刊名：中国肿瘤临床

外文期刊名：Chinese Journal of Clinical Oncology

收录：;北大核心:【北大核心2023】；

基金：甘肃省卫生健康行业科研计划项目(编号:GSWSKY2023-80);兰州市城关区科技计划项目(编号:2023SHFZ0022)资助。

语种：中文

中文关键词：结直肠癌;靶向治疗;免疫治疗

外文关键词：colorectal cancer(CRC);targeted therapy;immunotherapy

摘要：结直肠癌(colorectal cancer,CRC)是消化系统常见的恶性肿瘤,全球发病率和死亡率不断上升,CRC的标准治疗方法为手术、化疗和放疗。然而,上述治疗方法对晚期转移性结直肠癌(metastatic colorectal cancer,mCRC)患者而言不良反应较大。因此,探索更多可替代的有效治疗方法至关重要。近年来,随着分子技术的发展,越来越多的生物标记物被发现,靶向和免疫治疗在mCRC治疗领域取得了较好的成绩,靶向和免疫治疗的患者预后和生存质量也更佳。基于此,本文综述了mCRC靶向和免疫治疗最新研究进展,为mCRC的精准治疗提供参考。
Colorectal cancer(CRC)is a common malignancy of the digestive system,with increasing morbidity and mortality worldwide.The standard treatment for CRC has,in the past,been surgery,chemotherapy,and radiotherapy.However,these treatments have significant side effects and are particularly challenging for patients with advanced metastatic CRC(mCRC).Therefore,it is crucial to explore alternative and more effective treatments.In recent years,with the development of molecular technology,numerous biomarkers have been identified,and targeted therapy and immunotherapy have achieved surprisingly positive results in the treatment of mCRC.Patients receiving targeted therapy and immunotherapy have an improved prognosis and quality of life.On this basis,this article reviews the latest research progress in targeted therapy and immunotherapy for mCRC,providing a reference for precision treatment of mCRC.